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Act on Axial SpA:   
A Gold Standard 
Time to Diagnosis
“Aged 17, I saw a rheumatologist. 
I had been in pain for five years, 
and I was exhausted. I could see 
no hope of living in any other way. 
Today, with a diagnosis, 
I’m living my best life.” 
 
Bethany
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Calling Time on Delay  
– A Gold Standard Approach 
In July 2019, I was in Parliament 
for a meeting with parliamentary 
officers of our newly formed 
All Party Parliamentary Group 
(APPG) on axial SpA.
They asked me to explain all of the 
reasons for the delay to diagnosis in 
axial SpA and to offer a route map of 
solutions to address them. I left the 
meeting feeling that I hadn’t answered 
their questions satisfactorily.  
I reflected on the literature, where 
studies on delayed diagnosis tend to 
talk about ‘factors associated with 
delay’, but what they don’t typically 
do is follow the journey of the person 
living with axial SpA to understand 
that journey from the moment of 
symptom onset to diagnosis.
With that realisation in mind,  
I approached two of our medical 
advisors, Prof. Karl Gaffney and  
Dr. Raj Sengupta, and we worked 
together to map out the delay to 
diagnosis from a ‘follow-the-patient’ 
perspective, identifying four broad 
sets of delays. We then created a set 
of proposals to address each of these, 
and wondered what quantum of time 
to diagnosis might be achievable if our 
proposed solutions were implemented 
effectively. We concluded that it 
should be feasible for someone to be 
diagnosed with axial SpA within  
12 months of symptom onset, and set 
out to develop a written proposal for a 
Gold Standard time to diagnosis with a 
target of one year.
I then approached colleagues at 
UCB who shared our aspirations and 
emerging strategy and encouraged 
me to consider a five year timescale 
in which we could develop a Gold 
Standard proposal and implement 
its recommendations in full. Spurred 
on by the possibility of a larger 
programme of work that would have 
the potential for significant impact, we 
began to test out the idea of a gold 
standard approach in collaboration 
with clinicians. I was heartened by 
how positively the idea was received, 
and developed a growing sense that 
a Gold Standard approach might 
galvanise efforts to improve diagnosis 
in axial SpA. 
Dr. Sengupta announced our 
ambitious goal at a meeting of the 
APPG in January 2020, and in July 
we launched a national consultation 
process to engage patients, clinicians, 
commissioners and policymakers, 
seeking their response to a document 
we developed to set out our ideas.  
The 202 responses to the consultation 
confirmed that we were on the right 
track and led us to develop more 
specific proposals which we began to 
test out in the early part of 2021. My 
grateful thanks to all of those people 
who have contributed in various ways 
to the consultation and programme 
development process, culminating in  
a consensus development workshop 
in May 2021.
This report outlines our final set of 
proposals to achieve a Gold Standard 
of one year, under the campaign 
name Act on Axial SpA. We will work 
closely with people living with axial 
SpA, primary and community care, 
secondary care, professional bodies, 
commissioners, Parliamentarians and 
policymakers as our campaign seeks 
to focus and streamline efforts to 
achieve earlier diagnosis. The report 
set out proposals for programmes 
addressing public awareness of axial 
SpA, healthcare practitioner education, 
referral pathways, and service quality 
improvement in order to improve 
patient experience, diagnosis and 
outcomes.
The campaign website,  
actonaxialspa.com, provides an online 
resource which we hope will become 
the largest and most comprehensive 
resource on axial SpA diagnosis 
anywhere in the world. It contains 
information and diagnosis support 
tools for the public, including an online 
symptom checker, as well as newly 
created and curated resources for 
healthcare professionals (HCPs), 
which guide them through research 
articles, best practice examples, 
quality improvement tools and case 
studies for each of our four solutions 
as we follow the patient journey.
We are publishing this report at a 
time when the UK is beginning to 
emerge from the Covid-19 pandemic. 
In England, the Best MSK Health 
Collaborative has been established 
to restore and improve MSK 
services and reduce the variation 
in service provision. One of the 
collaborative’s outputs is a new axial 
SpA pathway and we were involved 
in its development. Act on axial 
SpA will encourage the widespread 
implementation of the pathway in 
order to achieve earlier diagnosis. 
The APPG on axial SpA will continue 
to press the case for early diagnosis 
and raise the profile of the condition 
within Parliament. In Scotland, we 
continue to work through the Cross 
Party Group on MSK Health, in 
Wales we will work with the newly 
established MSK Pathway Steering 
Group and in Northern Ireland we will 
seek opportunities to engage the 
administration. 
My heartfelt thanks to those 
organisations that have given their 
support to this document; over the 
coming months we will call for every 
NHS organisation and relevant 
professional body to endorse 
it and commit to supporting its 
implementation. My thanks to the 
Chair and Co-Chair of the APPG - 
Tom Randall MP and Lord Campbell 
Savours – former APPG Chair, 
Derek Thomas MP and all of the 




average delay to 
diagnosis from when 
symptoms start is 
8.5 years, during 
which irreversible 
damage to the spine 
may have occurred.
Years to diagnosis
I want to acknowledge the 
phenomenal leadership and  
vision of our clinical collaborators  
Prof. Karl Gaffney and Dr. Raj Sengupta, 
and also thank Dr. Stephen Zhao 
and Rosie Barnett for their incredible 
help and support on the background 
literature and documentation and 
Nick Clarke who provided a patient 
perspective. This programme would 
not have been possible without the 
outstanding and steadfast support of 
UCB whose commitment, passion and 
insight has been incredibly energising. 
Finally, I want to thank the outstanding 
team at NASS who have worked 
tirelessly for the best part of a year to 
bring this ambitious programme to life, 
and in particular Dr. Lisa Swinger and 
Liz Marshall. Thank you! 
 
 
Dr. Dale Webb, FRSA, FRSPH 
CEO, NASS
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“As an MP living with  
axial SpA, I am excited  
to see this programme 
come to life. This will be 
the springboard to a better 
future for many young 
people and a vehicle to 
effect real change.”
Tom Randall, MP 
2021 In the Know
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Delayed diagnosis of axial SpA and its impact 
Axial SpA is more common than 
people realise, affecting 1 in 200 
adults in the UK, which is more than 
the number of people with multiple 
sclerosis and Parkinson’s disease 
combined (2, 3). The primary symptom 
is chronic lower back pain, for which 
between three and seven million GP 
consultations take place each year in 
the UK (4), therefore it is perhaps not 
surprising that this symptom alone 
does not immediately trigger thoughts 
of axial SpA.
People with axial SpA also often 
experience other symptoms as part 
of their condition, such as fatigue, 
morning stiffness, sleep disturbance 
and reduced function/mobility  
(5, 6), as well as other musculoskeletal 
manifestations (hip or hind foot 
arthritis, enthesitis, dactylitis and 
extra-skeletal manifestations 
including acute anterior uveitis (AAU), 
inflammatory bowel disease (IBD),  
and psoriasis in one-third of patients 
(7). All of these symptoms can impair 
quality of life further by adding 
considerable additional physical, 
emotional and economic burden. It 
is therefore critical that individuals 
receive the care that they need as 
soon as possible to improve their 
quality of life (8-12) and long-term 
outcomes. 
Sadly the current time to diagnosis 
in the UK averages 8.5 years from 
symptom onset (13) despite various 
guidelines and recommendations 
to improve referral of patients with 
chronic lower back pain, and two 
recent systematic reviews have 
found significant delays to axial SpA 
diagnosis worldwide with a global 
mean of 6.7 years (13-21). This delay 
is unacceptable. Axial SpA typically 
starts in the second or third decade 
of a person’s life, often derailing hopes 
and dreams at a critical time for 
attempting to establish careers and 
relationships (16). A delayed diagnosis 
during these formative years can 
therefore be extremely disruptive. 
Some people report not feeling 
listened to or believed about their 
symptoms, while others feel helpless 
and withdraw from care completely, 
leading to further diagnostic delay 
(17). People with delayed diagnosis 
may also suffer from a less favourable 
response to treatment and worse 
outcomes in disease activity, 
fatigue, function, spinal mobility and 
radiographic damage to the spine 
(8, 18-20). These individuals also 
experience difficulty sleeping and 
have a higher prevalence of mental 
health and psychosomatic disorders 
(20). One study demonstrated 
impaired spinal mobility to be twice as 
high in individuals with a diagnostic 
delay of over six years, in comparison 
to individuals diagnosed in less than 
six years (8). A recent systematic 
review of the literature found that 
people with delayed diagnosis also 
had a greater likelihood of depression, 
negative psychological impacts, 
work disability, worse quality of life 
and higher healthcare costs (8) and 
that the disease had a significant 
societal impact, due to economic 
factors such as work disability and 
healthcare cost. Diagnostic delay was 
consistently related to a higher risk 
of work disability or unemployment 
and associated with job loss (8). 
Specifically, one study in Ireland 
demonstrated that unemployment 
rose from 20% among people 
diagnosed with axial SpA within four 
years, to more than 40% among those 
with a delay of over 10 years.
Several factors have been 
independently associated with a 
longer diagnostic delay: including 
female sex, HLA-B27 negativity, lower 
education levels among patients, 
prior diagnosis of mechanical back 
pain, presence of uveitis, psoriasis 
or enthesitis and young age of 
symptom onset (18, 21-24). Presence 
of peripheral arthritis and IBD have 
been associated with earlier diagnosis 
and treatment (13, 25, 26) leading 
to better outcomes and treatment 
responses (18, 19). The shorter time to 
diagnosis in individuals with peripheral 
musculoskeletal manifestations 
is likely due to the fact that GPs 
have been consistently prompted 
via the early arthritis initiative to 
refer patients with swollen joints to 
rheumatology (13, 25, 26). This reflects 
the impact that educational tools 
can have on improving early referral 
to rheumatology for individuals with 
suspected inflammatory arthritis. 
Evidence emphasises the importance 
of recognising the condition early. 
We know that targeted awareness-
building and education can positively 
impact time to diagnosis. GPs were 
found to improve substantially the 
Axial spondyloarthritis (axial SpA) is a life-long inflammatory condition that primarily affects the 
spine and sacroiliac joints. The term axial SpA encompasses both ankylosing spondylitis (AS), 
where clear structural changes to the spine can be observed via x-ray, and non-radiographic 
axial spondyloarthritis (nr-axial SpA) which is diagnosed from other clinical features and magnetic 
resonance imaging (MRI) (1). The fact that cases present differently and may require different 
diagnostic approaches to confirm the disease is one of the first clues as to why diagnosis of this 
condition can prove challenging.
1 in 200 people  
in the UK have  
axial SpA making it 
more common than 
MS and Parkinson’s 
combined.
recognition and referral of people 
with suspected axial SpA (27, 28) 
after receiving education about SpA, 
with one recent multi-centre study 
demonstrating over 40% improvement 
in referral (27). Equally, among 
physiotherapists, good awareness 
of the NICE 2017 guidance on axial 
SpA and continuing professional 
development was associated with 
better awareness and knowledge of 
axial SpA features (29). 
Evidence suggests that we need to 
promote/provide sustained education 
and awareness among the public and 
healthcare professionals - as part of a 
broader set of change mechanisms - to 
ensure that axial SpA is at the forefront 
of clinical reasoning. It is therefore 
critical that initiatives designed to 
improve knowledge and awareness 
and to ensure early specialist referral 
and diagnosis are embedded and 
sustained within care pathways. 
Greater public awareness of axial SpA 
and its wide range of symptoms will 
also help to tackle this unacceptable 
delay to diagnosis. 
In the UK, people living with axial SpA wait an average (mean) of 8.5 years 
to receive their diagnosis (1, 2) This means that there are potentially 
thousands of people at any one time who are living with debilitating and 
painful symptoms, but with no agreed clinical explanation or treatment path.
A Gold Standard Approach
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Poppy
“Parenting my children was 10 
times more difficult and I got 
very low. Once I’d received 
my diagnosis and got the right 
treatment, I was able to trek 
along the Great Wall of China.” 
Rowena
“My pain became so bad that,  
at times, I couldn’t get out of bed. 
I relied on crutches to remain 
mobile. It’s amazing to think of 
that now. An earlier diagnosis 
may have prevented all of that.” 
Max
“Especially for younger people 
this diagnosis doesn’t mean 
your ambitions and goals have 
to disappear. With the right 
medication, and if you build 
healthy habits, it’s possible to 
live the life you want to lead.”
of individuals with 
axial SpA do not 
contact a healthcare 
practitioner within 




The patient journey to diagnosis
A person with back pain does not 
realise that it might be axial SpA
Axial SpA represents a relatively 
uncommon cause of a very common 
symptom – chronic lower back pain 
(30). Up to 80% of the population 
may experience back pain at some 
point within their lifetime. Thus, many 
individuals with undiagnosed axial 
SpA, lacking awareness of axial SpA, 
attribute their symptoms to over-
exercise, injury or other life stressors; 
only two thirds of people with axial 
SpA report contacting a healthcare 
practitioner within 12-months of 
developing symptoms (31).  
Many individuals attempt to  
self-manage their condition until either 
self-management fails or the condition 
worsens, and they are prompted to 
seek professional advice (32-34). 
Furthermore, those who have sought 
clinical help but remain undiagnosed 
often feel dismissed or unheard by 
the healthcare system and cease to 
come forward for long periods, as their 
disease worsens.
Primary care practitioner may not 
recognise axial SpA
People with undiagnosed axial SpA 
usually first present with chronic lower 
back pain to their general practitioners 
(GPs) or other non-rheumatology 
primary care providers. However, 
there is a low level of specialist 
knowledge of axial SpA in primary 
care (29, 35-40). Approximately 40% 
of people with axial SpA also report 
seeking treatment pre-diagnosis 
from osteopaths or chiropractors, 
many of whom may not have 
specialist knowledge on axial SpA 
(41). In addition, in a recent survey of 
chiropractors and osteopaths, the 
principal perceived barrier to onward 
referral was reluctance by the GP 
to accept their professional opinion 
(16). Patients may also find difficulty 
conveying their symptoms, and as 
reported in patient interviews  
(17, 32) have experienced negativity 
or reluctance from GPs to investigate 
further. 
Common misconceptions about axial 
SpA also remain in primary care. The 
Oxford Handbook of General Practice 
still refers to late stages of axial 
SpA, with a focus on males and late 
disease features such as fusion of the 
spine and SIJs (42). This perspective 
persists from historical knowledge of 
the disease, for example its strong 
genetic association with the human 
leukocyte antigen B27 (HLA-B27) gene; 
yet up to 25% of axial SpA patients 
are HLA-B27 negative (43). Women 
are more likely to be HLA-B27 negative, 
contributing to the perception that it 
is a predominantly male disease. Also, 
the presence of radiographic changes, 
historically critical for identifying 
ankylosing spondylitis (AS), are more 
common in males. But we now know 
that early disease does not usually 
display as structural bony changes 
on radiographs, and ~50-70% of 
individuals with this non-radiographic 
axial SpA are female. Despite this 
knowledge, a recent study reported 
that GPs still believe that AS is almost 
exclusively a male disease (35). 
Person with symptoms suggestive 
of axial SpA is not directly referred to 
rheumatology services
A 2019 APPG inquiry found that only 
21% of the 191 clinical commissioning 
groups (CCGs) and 99 provider Trusts 
had a specific inflammatory back 
pain pathway from primary care 
to rheumatology (44). Without this 
pathway, many cases of unexplained 
chronic back pain may be referred 
to orthopaedics or chronic pain 
management services, leading to 
unnecessary, ineffective treatments 
or even surgery (45). 
Similarly, consultants in 
ophthalmology, gastroenterology 
and dermatology respectively miss 
axial SpA symptoms in individuals 
presenting with AAU, IBD and 
psoriasis, each of which, as an extra-
skeletal manifestation of axial SpA, 
could be indicative of the disease. In 
the multicentre Screening for Axial 
SpA in Psoriasis, Iritis (AAU), and Colitis 
cohort, 48% of people with psoriasis, 
AAU or colitis, <45 years of age with 
>3 months undiagnosed back pain 
were diagnosed with axial SpA if using 
a three-stage evaluation approach 
(clinical evaluation, laboratory results 
[HLA-B27, CRP] and radiography, MRI) 
(46); 69% were diagnosed with axial 
SpA after the clinical evaluation alone 
(47). These figures suggest that many 
opportunities to identify, diagnose and 
treat axial SpA are being missed.
Rheumatologist may not have the 
most up-to-date understanding 
of axial SpA and appropriate 
investigations
The diagnosis of axial SpA is complex, 
whereby individual symptoms or tests 
in isolation are insufficient to either 
diagnose or rule out axial SpA; rather 
a combination of axial SpA symptoms, 
physical examination, appropriate 
diagnostic tests and imaging should 
lead to diagnosis. However, not all 
rheumatologists have specialist 
knowledge of axial SpA or feel 
confident implementing or interpreting 
the appropriate investigations, 
particularly MRI scans. Just one-
third of NHS hospitals perform the 
recommended MRI protocol for axial 
SpA (48, 49). Interpretation of MRI is 
also challenging and depends on the 
expertise of the radiologist. A recent 
study found inconsistencies in the 
use of MRI in clinical practice (50) 
resulting in challenges in interpretating 
MRI in diagnosis (50, 51). However, 
consensus recommendations for 
MRI use in the diagnosis of axial 
SpA have been published (51). Their 
adoption, supported by training of 
rheumatologists/radiologists in the 
interpretation of MRI in the context 
of suspected axial SpA, should help 
standardise practice and achieve 
consistent, reliable diagnosis (52). 
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A national consultation process 
Over an 11 month period we undertook 
a national consultation process which 
included people living with axial SpA, 
healthcare professionals, professional 
bodies, communications experts 
and commissioners. We undertook a 
scoping literature review, then created 
a consultation document which 
set out our analysis and proposals 
(53). We created a survey and sent 
it and the consultation document 
to hundreds of organisations 
and individuals. We received 202 
responses with all respondents 
supporting the principles behind the 
proposals and the aspiration for a 
Gold Standard time of one year.
We had to adapt our consultation 
processes in light of the Covid-19 
pandemic and we were especially 
grateful that clinicians were able 
to remain engaged despite the 
enormous pressures that the 
pandemic created on the NHS. 
We held a workshop with public 
health specialists, journalists and 
documentary makers and other 
communications experts to develop 
our thinking about public awareness 
campaigning. We invited a group 
of stakeholders to comment on a 
‘concept note’ for a primary care 
champions programme. In May 2021 
we held a consensus development 
workshop with 75 stakeholders to 
share our draft final recommendations 
and seek their input. 
An integrated campaign using 
multiple change levers
• There is a wealth of literature 
suggesting that the key to creating 
sustainable improvements in 
healthcare is an integrated whole-
system approach that uses multiple 
change levers (54). Act on axial SpA 
employs a multi-lever approach, 
building on work that NASS has 
already begun. The campaign 
should, therefore be viewed in a 
holistic way.
• First, are the top down or extrinsic 
levers, typically governmental 
approaches that include legislation, 
regulation and performance 
management systems. In 2019 
NASS worked with Parliamentarians 
to form the axial SpA APPG with 
the specific intention of creating a 
top down lever that would seek to 
ensure the effective implementation 
of the NICE Guideline on the 
diagnosis and management of 
spondyloarthritis. Act on axial SpA 
will periodically report progress to 
the APPG.
• Top down levers are balanced by 
bottom up levers that tap into the 
intrinsic motivators of clinicians 
that want to provide the best 
for their patients. In 2019 NASS 
created Aspiring to Excellence 
to provide rheumatology teams 
with the quality improvement 
tools and support to improve 
care at local level. Most of the 
11 hospitals involved are trialling 
different approaches to reducing 
time to diagnosis and may provide 
examples of best practice as the 
campaign unfolds.
• Economic levers such as 
incentives, sanctions, 
competition, drug pricing 
and patient choice are 
used to influence 
commissioning and 
clinical behaviours. 
Act on axial SpA 
is currently 
commissioning a research study 
to estimate the full economic costs 
of delayed diagnosis in the UK in 
order to influence policy makers 
and commissioners and use in our 
Parliamentary lobbying.
• Professional levers include 
education and training, clinical audit, 
peer review and guidelines. The UK 
has multiple initiatives including 
regional SpA Academies, the 
National Early Inflammatory Arthritis 
Audit and the Getting it Right First 
Time programme. 
Another way to articulate this is to 
propose that interventions are either 
system focussed or people focussed. 
Some might argue that one or the 
other is more important, and indeed 
the debate about whether behaviour 
is shaped more by social structure 
or human agency is one that has 
occupied sociologists since Weber 
and Durkheim in the late 19th century.
Act on axial SpA draws on both sets 
of interventions: system interventions 
including referral pathways to simplify 
and standardise care, and the use 
of automation in electronic patient 
records, and people interventions 
including an online symptom checker 
for those with potential axial 
SpA and checklists for staff in 
secondary care services. 
The roadmap to reducing delay to diagnosis
Driving change
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The Driver Diagram (below) summarises our thinking on the 
four primary changes that the campaign seeks to achieve, 
the strategy to achieve each of them and then the specific 
interventions required to ensure that we achieve our goal. 
The remainder of this document sets out those proposals in 
greater detail.
Help the person with 
inflammatory back pain 
to recognise that it might 
be axial SpA and feel 
confident about the 
actions they should take
Ensure that patients 
who present at primary 
care and community 
physiotherpay services 
with potential axial SpA 
are appropriately identified 
and urgently referred to 
rheumatology
Ensure quick and accurate 
diagnosis of axial SpA in 
rheumatology
Ensure that patients who 
present at secondary care 
services with suspected 
axial SpA are identified 
at the first presentation 
and urgently referred to 
rheumatology
In order to achieve  
this aim...
We need to 
ensure...
Promote axial SpA pathway recommended by Best MSK Health Collaborative
Develop public awareness campaigns. 
 Use the SPINE acronym and encourage its adoption
Create an 8-item online symptom checker
Support patients in preparing for their primary care consultation 
Create and strong visible leadership for axial SpA through a  
Primary Care Clinical Champions Programme
Ensure axial SpA is a core component of CPD in primary care 
Promote the use of the 8-item criteria & SPADE tool
Test and roll-out pop-up tools on electronic patient record system
Create a national training programme, co-developed with relevant professional  
associations to be implemented at a local level. Promote use of the 8-item 
symptom checker & SPADE tool 
Promote the use of appropriate secondary referral pathways,  
and share best practice across the UK
Promote the routine implementation of appropriate imaging protocols using  
the BRITSpA consensus guidelines
Review the status of radiology training in UK for axial SpA and audit the  
use of an inflammatory spinal protocol MRI 
Work with professional bodies to ensure updated and expanded training to  
improve diagnostic capabilities and case studies
Assess the availability of regional MDTs offering axial SpA virtual imaging to  
secondary care across the UK via tertiary referral
Actions to ensure this happens
Greater public awareness of axial 
SpA symptoms 
Advice is avaiable to the public on preparing for  
their primary care consultation
Axial SpA to be higher within clinical 
reasoning of primary care professionals 
Appropriate use of diagnostics  
by referrers
Use of IT systems to identify potential  
axial SpA among patients with back pain 
Inflammatory back pain referral 
pathways are in place
The public can check their 
symptoms easily online 
Secondary care services are aware of axial spa  
symptoms and how to assess if the patient 
merits referral to rheumatology
Every relevant secondary care service has a 
rheumatology referral pathway and knows  
when/how to use it
Every hospital in the UK seeing potential axial 
SpA patients has an inflammatory spinal 
protocol MRI in place
Which requires...
Every rheumatologist in the UK is able to 
access an axial SpA expert MSK radiologist 
in house or via another specialist centre
All radiologists/rheumatologists are aware  
of BRITSpA MRI guidelines
Improve time  
from symptom  
onset to  
diagnosis to a 
maximum  
of 12 months
The first delay to diagnosis of axial 
SpA is late presentation by the 
patient to primary care. Improving 
public awareness of the condition 
and its sign and symptoms, and 
understanding what to do if one 
has the correct symptoms, is critical 
to achieving earlier presentation in 
primary care.
Public awareness campaigns
We encourage NHS organisations, 
professional bodies, and private 
and public sector organisations 
to support the Act on Axial SpA 
campaign which has been designed 
to target people who are aged 40 
and under in particular. Its aim is 
to help people understand the 
condition and its symptoms, empower 
people to consult primary care at 
the earliest opportunity and make 
clear the referral pathway if the 
primary care professional suspects 
axial SpA. The campaign will seek 
to create a sense of urgency but 
without scaremongering. The core 
components of the campaign  
strategy are:
• A clear articulation of the 
problem: On average it takes over 
eight years for axial SpA to be 
diagnosed. This is too long. Every 
year that passes without diagnosis 
can lead to deeper damage.
• A defined campaign purpose: 
To reduce the average time to 
diagnosis to one year.
• A definition of how we will 
achieve our ambition: The 
campaign will ensure that the 
public recognise the symptoms of 
axial SpA, know what to do next 
and what should happen if the 
healthcare professional suspects 
that they have axial SpA.
• A core campaign concept of  
‘a race to stop the progress of the 
condition’ will underpin all of the 
campaign communications.
Helping someone with inflammatory back pain 
to recognise that it could be axial SpA and feel 
confident about the actions they should take
General public awareness of axial SpA and its symptoms 
is significantly improved. People with chronic, low-back 
pain lasting longer than three months - particularly 
those aged 40 and under - are aware that it could be 
related to axial SpA and are motivated to consult their 
GP/primary care professional at the earliest opportunity 
and within four months of symptom onset. The public 
can easily check their symptoms online, feel empowered 
and are aware of the referral pathway if the primary care 
professional suspects axial SpA.
Our vision: 
Stories about people who have 
faced a long delay to diagnosis 
will be central to the campaign 
communications across all platforms, 
bringing the issue to life. The campaign 
will adopt a phased test and learn 
approach, to see what works most 
effectively in terms of messaging 
and delivery, and from there will 
make informed decisions regarding 
investment in bigger, more ambitious 
tactics. 
Phase one communications to drive 
public awareness will test the act on 
axial SpA brand and key messaging 
and will include:
• A media relations programme, 
with an emphasis on the TV, 
radio programmes, podcasts and 
publications likely to be trusted by 
our target audience.
• Social media activity targeted by 
age: Instagram for those under 25s 
and Facebook for 25-45s. 
• Engaging with social media 
influencers to primarily reach the 
under 25s audience.
• Community poster campaign 
across community centres, GP 
surgeries, leisure centres and other 
places that the key audience 
groups are likely to visit.
Phase Two is likely to include a 
concentrated local campaign in 
a single area, combining learning 
from Phase One and adding new 
communication tactics such as 
outdoor advertising, with a particular 
emphasis on public transport hubs.  
If these tactics result in an increase  
in rheumatology referrals the 
campaign may be extended to other 
parts of the UK.
“At first, I just thought 
I had sports injuries, 
nothing serious. 
Over the years, I saw 
doctors, physios and 
chiropractors who put 
my chronic pain down 
to sport injuries, growing 




Delay to diagnosis of axial SpA is 
linked to poorer outcomes including 
greater functional impairment and 
higher prevalence of depression  
(8,18,20) 
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SPINE will be widely used in the act on axial SpA campaign and 
we encourage all supporting organisations to adopt the acronym in 
awareness raising work with the general public. 
Axial SpA is a complex condition to 
articulate and explain. To be successful 
in engaging the public requires a 
graduated approach to communication 
which takes the audience through an 
information journey, as follows: 
• State what the condition is and raise 
awareness that someone’s back pain 
might be axial SpA.
• Set out a small number of key 
symptoms that will resonate with the 
public and be easy to remember.
• Identify a larger number of symptoms 
which have a high degree of sensitivity 
and specificity and which provide a 
sound basis for recommending that 
the person consults primary health 
care. 
To that end, act on axial SpA has 
developed the SPINE acronym, which 
sets out the following key symptoms:
14
The SPINE acronym
Did your back pain start before the 
age of 40? YES
Did your back pain develop 
gradually? YES
Has your back pain lasted more than  
3 months? YES
Do you experience stiffness in your 
back in the morning for at least 30 
minutes? YES
Does your back pain improve when 
you move around? YES
Does your back pain improve when 
you rest? NO
Do you have pain in your buttocks, 
which moves from one buttock to the 
other? YES
Do you wake in the second half of 










An eight-point set of inflammatory back pain 
criteria and online symptom checker
The campaign communications goes beyond 
media messaging and creates value for 
audiences by empowering people to explore 
the condition and their symptoms via a new 
online resource actonaxialspa.com. On the 
website, people can use an online symptom 
checker. It employs an eight-point set of 
inflammatory back pain criteria that combine 
the three extant validated sets of criteria  
(55-57). If the person gives the correct 
response to five or more items (see right) they 
will then be given information about consulting 
primary care.
Supporting patients in preparing for their  
primary care consultation
Actonaxialspa.com will include a range of 
resources for people to advise them about the 
need to book a primary care consultation. It will 
provide a print-out of the symptom checker 
results - with an explanation for the primary 
care professional on the criteria used.
A Gold Standard Approach
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Primary care and community services 
have a key role in identifying patients 
with suspected axial SpA and referring 
them directly to rheumatology. Most 
people with suspected axial SpA 
will consult primary care in the first 
instance, and around 5% of patients 
with chronic back pain attending 
primary care are estimated to have 
axial SpA (58). However, people with 
axial SpA frequently report to NASS 
that their primary care professionals 
failed to identify their axial SpA, 
misdiagnosing it as mechanical pain or 
sometimes ascribing psychosomatic 
reasons. 
Primary healthcare professionals 
report numerous barriers to 
diagnosing axial SpA, including low 
prevalence, the lack of a definitive 
diagnostic test, the slow progression 
of the condition and the intermittent 
nature of the pain that patients 
experience (59). Even amongst 
MSK physiotherapists, awareness, 
knowledge and confidence in 
Ensuring that patients who present at primary 
and community care with potential axial SpA are 
appropriately identified and urgently referred to 
rheumatology
All patients who present to primary care with suspected 
axial SpA are appropriately identified and urgently referred 
to rheumatology, as set out in a local inflammatory back 
pain referral pathway. Axial SpA is higher within the 
clinical reasoning of primary care professionals, supported 
by alerts on electronic patient records which prompt 
consideration of axial SpA for appropriate patients. Within 
England, there is widespread adoption of the Best MSK 
Health Collaborative axial SpA pathway.
Our vision: 
“At the start of your 
GP appointment, 
explaining you are really 
concerned that you 
might have axial SpA is 
super helpful, ensuring 
you get what you need.” 
 
Dr Daniel Murphy, GP,  
Devon, UK
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screening for suspected axial SpA 
and referring to rheumatology is low, 
and a recent study concluded that 
this group of professionals may not be 
giving adequate consideration to axial 
SpA in back pain assessments (29).
A recent national inquiry into axial SpA 
services in England led by the APPG 
for axial SpA found that only 15% 
of CCGs have specific programmes 
in place for educating primary care 
professionals about axial SpA (60).
Consequently, axial SpA is likely to  
be low within the clinical reasoning  
of most GPs and MSK clinicians and 
the condition lacks visibility within 
primary care.
Strong, visible clinical leadership for 
axial SpA at local level in primary care
To strengthen clinical leadership and 
visibility for axial SpA in primary care 
and community services, we will 
create and support a cadre of clinical 
champions including First Contact 
Practitioners, GPs, community MSK 
physiotherapists, nurse practitioners 
and others. They will receive 
leadership development, training in 
using quality improvement methods, 
and support to identify and implement 
improvement projects within their local 
healthcare system. They will work 
together in a national learning network 
to foster community-building, the 
exchange of ideas and good practice 
and they will act as catalysts for 
change.
Axial SpA clinical champions will be 
active within the wider healthcare 
system, connecting to the national 
policy environment. Axial SpA 
clinical champions will co-produce 
a body of knowledge, methods, 
tools and experience and work to 
share their learning with primary 
and community services across 
the UK, collaborating with relevant 
professional bodies. They will promote 
relevant frameworks including the 
forthcoming rheumatology specialist 
physiotherapy Competency 
Framework (61).
Participating clinical champions will 
benefit from enhanced leadership 
skills and greater confidence in 
undertaking service improvement 
work. They will develop their 
networking skills and enlarge their 
professional network. They will gain 
access to resources and expertise 
as well as create new resources 
for other healthcare professionals. 
Their work will directly result in 
earlier identification of patients with 
suspected axial SpA and quicker 
referral to rheumatology. We also 
anticipate benefits in terms of better 
primary care management of axial 
SpA patients: with an up-skilled 
primary care workforce, one would 
expect to see a better understanding 
of medication, exercise, fatigue and 
mental health in axial SpA. 
Axial SpA as a core component of 
continued professional development 
Act on axial SpA will work in 
partnership to encourage the 
prioritisation of MSK as a core 
component of continued professional 
development within primary care and 
to ensure screening for inflammatory 
conditions. The campaign will support 
Health Education England’s Primary 
and Community Care Training Hubs, 
workforce education initiatives in 
NHS Education and Improvement 
Wales, and NHS Education for 
Scotland. We will promote our online 
resource, actonaxialspa.com, which 
brings together a wide range of 
educational resources for primary 
care professionals. The campaign will 
disseminate and embed axial SpA 
resources that are developed through 
the primary care clinical champions 
programme. 
We want to ensure that primary care 
referrers have access to and use 
appropriate tools: we will promote the 
eight-item inflammatory back pain 
(IBP) criteria as well as the SPADE 
tool (www.spadetool.co.uk) which 
has been designed to assist medical 
professionals define the probability 
of axial SpA in a patient with chronic 
back pain, below the age of 40. 
Primary care information systems 
that can flag patients with suspected 
axial SpA 
To support primary care professionals 
to identify appropriate patients 
early, we will support the uptake 
of a pilot project in Bath that has 
successfully implemented a tool 
on the GP electronic patient record 
system. Under this pilot, when a 
GP types “back pain” the system 
checks whether the person is under 
the age of 45, and whether they 
have previously had back pain. If the 
answer to these is yes, it prompts 
consideration of axial SpA. It can also 
be programmed to alert the GP of 
possible axial SpA if the patient has 
had AAU, psoriasis or IBD in the past.
Widespread adoption of the Best 
MSK Health Collaborative axial SpA 
pathway 
The Best MSK Health Collaborative 
was developed in 2021 by NHS 
England and Improvement and is 
led by the National Clinical Director, 
Musculoskeletal Conditions. It seeks 
to restore and improve MSK services 
and reduce the variation in service 
provision. One of the Collaborative’s 
outputs is the development of 
an axial SpA pathway. It reflects 
recommendations in this document, 
and is now being promoted to 
NHS regions. The campaign will 
promote the widespread adoption 
of the pathway and will monitor its 
implementation through Freedom of 
Information requests.
A Gold Standard Approach
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Patients with suspected axial SpA who present 
at a range of services - including ophthalmology, 
gastroenterology, dermatology, orthopaedics - are 
identified at the first presentation and urgently 
referred to rheumatology. Relevant secondary care 
services should be aware of axial SpA symptoms 
and how to assess if the patient merits referral to 
rheumatology. Every UK hospital seeing potential 
axial SpA patients should have a rheumatology 
referral pathway, and all specialists know when/
how to use it.
Our vision: 
Ensuring direct referral to rheumatology for patients 
with suspected axial SpA attending secondary 
care services
Given the high prevalence of 
peripheral and extra-musculoskeletal 
manifestations of axial SpA, 
clinicians across ophthalmology, 
gastroenterology, dermatology and 
orthopaedic spinal surgery have a key 
role in screening undiagnosed patients 
for referral to rheumatology. These 
specialists may not be familiar with 
axial SpA or know how to assess for 
its probability. If they do suspect axial 
SpA, they may reroute the patient 
back to the GP or follow a standard 
18-week secondary referral route, all of 
which adds to delay.
A national training programme 
The act on axial SpA campaign will 
develop a national training programme 
for secondary care services to be 
implemented at a local level, led by 
rheumatologists and their teams. 
It will be developed in consultation 
with the professional organisations 
representing these specialist 
disciplines, piloted across the NASS 
Aspiring to Excellence sites and 
then refined for national roll-out. We 
envisage that the education package 
will resonate most effectively through 
a combination of online access to 
learning and face to face teaching 
sessions on site at the hospital base, 
such as lunch-time seminars on 
axial SpA signs and symptoms as 
well as reviews of real case studies 
on delay. The campaign will support 
rheumatology teams with promotional 
materials to promote the training 
delivery and its key messages. 
The programme will create a set of 
learning tools to raise awareness of 
axial SpA symptoms and to ensure 
that the condition is on the checklist at 
first presentation of a new referral. A list 
of screening questions to raise during 
the consultation will also be provided. 
The programme will include statistics 
on the likely incidence of undiagnosed 
axial SpA among new patient referrals. 
It will also create a toolkit to help 
rheumatology teams with the delivery 
of the educational package (digital/
online and face to face). There will be 
a targeted media and professional 
communications programme 
including presentations, exhibitions 
and poster case studies at events. 
The educational programme will be 
designed with sustainability in mind, 
to help ensure that the education 
of healthcare professionals in these 
disciplines can be embedded into local 
NHS practice. 
Internal referral pathways 
To reduce diagnostic delay, it is vital 
that specialists who suspect axial 
SpA are aware of and use their 
hospital’s internal referral pathway to 
rheumatology, rather than sending the 
patient back to their GP. The campaign 
will audit this through Freedom of 
Information requests. Where there 
are gaps, we will engage with the 
relevant CCGs, Locality Networks, 
NHS Boards, Local Commissioning 
Groups, hospitals and regional NHS 
bodies to encourage implementation 
of appropriate referral infrastructure/
training. The referral pathway and 
its use will be promoted through the 
education programme. 
Sharing best practice of referrals 
The campaign will collect best 
practice examples of relevant referrals/
pathways, creating digital publications 
and promoting these widely among 
the relevant stakeholder groups 
via actonaxialspa.com. It will build 
awareness of the website amongst 
our target healthcare professional 
audiences and ensure the highest 
quality data, clinical practice 
information and evidence-based best 
practice learning is made available 
to them to enhance their axial SpA 
diagnostic capabilities.
of individuals with IBD 
may have axial SpA
(62)
up to 
patients with acute 
anterior uveitis (AAU) 
may have axial SpA
(60, 61)
of individuals with 
with psoriatic arthritis 
may also fulfil criteria 
for axial SpA
(63)
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“Pain had been my  
reality for such a long  
time I didn’t know what  
was normal. At this  
point the rheumatologist 
diagnosed me with  
non-radiographic  
axial spondyloarthritis.  
 
I had mixed emotions.  
I was over the moon to  
have an answer but  
all I really wanted to get  
was a diagnosis and  
a magic pill to cure me”  
Max
Photograph by: Jonathan Blackham
The delays when the patient is being 
assessed by rheumatology span 
several aspects of diagnosis, including 
the use of biomarkers, the application 
of classification criteria, imaging 
choices and the interpretation of 
these results (Figure 1). Our solutions 
to help reduce delay are focused 
primarily on the issue of imaging 
challenges and how these impact a 
swift and accurate diagnosis. Some of 
the imaging challenges include: 
Inconsistencies in MRI acquisition: just 
one-third of NHS Trusts perform the 
recommended MRI protocol for axial 
SpA (48, 49). 
High inter- and intra-observer 
variability when assessing 
conventional SI joint X-rays (62-67). 
Lack of significant improvement in 
reproducibility and performance of 
identification of radiographic sacroiliitis 
after training (62). 
Lack of agreement around what 
constitutes a ‘positive’ MRI suggestive 
of axial SpA (68, 69) potentially 
leading to over-diagnosis or 
misclassification if used for diagnostic 
purposes without context (68, 70-77). 
 
Ensuring quick and accurate diagnosis of axial SpA 
in rheumatology 
Every hospital in the UK seeing potential axial SpA 
patients has an inflammatory spinal MRI protocol 
in place. Every rheumatologist in the UK is able  
to access an axial SpA expert MSK radiologist  
in-house or via another specialist centre.  
 
All radiologists and rheumatologists are aware of 
and use the BRITSpA MRI guidelines. 
Our vision: 
Lack of general awareness of the 
term axial SpA among UK radiologists: 
survey responses of 269 UK 
radiologists found that just 75% were 
aware of the term axial SpA and only 
31% and 25% were aware of the ASAS 
definitions of positive MRI for the SI 
joints and spine, respectively (50). 
Consensus recommendations for the 
acquisition and interpretation of MRI in 
the diagnosis of axial SpA have been 
recently developed by BRITSpA (51). 
Their national implementation should 
help standardise practice and allow for 
a more consistent, reliable approach 
to diagnosis (51). Radiologists have 
an important role in the diagnostic 
pathway; therefore their engagement 
alongside rheumatologists will 
be critical. The imaging problems 
described call for better training of 
rheumatologists and radiologists in 
the use and interpretation of MRI in 
the context of suspected axial SpA 
(52). We will also identify and promote  
best practice examples of NHS Trusts 
and regional rheumatology/radiology 
MDTs that meet to discuss complex 
complex and challenging cases.
Imaging  
difficulties
• Challenging to assess SIJ 
x-rays/MRI, high inter-/intra-
observer variability 




• Classification criteria not 
intended for use as a 
diagnostic tool 




• CRP lacking sensitivity/ 
responsiveness




Understanding the radiology  
axial SpA diagnostic landscape 
across the UK 
The campaign will work with relevant 
national bodies to review radiology 
training in axial SpA as well as audit 
the use of an inflammatory spinal 
protocol MRI through a Freedom of 
Information request to hospitals. This 
will deliver a full understanding of the 
current UK curriculum/opportunities on 
radiology diagnostics for axial SpA, for 
all levels of HCPs. It will also indicate 
which hospital sites require an MRI 
protocol update. 
Updating radiology axial SpA 
diagnostics training curricula 
Act on axial SpA will develop an 
up-to-date axial SpA MRI training 
programme, co-developed with 
rheumatologists and radiologists 
and endorsed by the British Society 
for Skeletal Radiologists, the British 
Society for Rheumatology and the 
Royal College of Radiologists. it will 
encourage professional organisations 
to update and expand their own 
training materials and promote 
guidance to reach undergraduate 
medical students, foundation and 
specialty HCPs. The campaign will 
support ongoing accreditation training 
and voluntary expert additional training 
via the NHS or professional bodies/
third parties. It will provide training 
materials through online learning, face 
to face teaching sessions on-site at 
the hospital and case studies. Using 
the BRITSpA consensus papers (50, 
51) the campaign will promote best 
practice for the routine implementation 
of appropriate imaging protocols. 
Utilising rheumatology and radiology 
services with axial SpA expertise  
or capacity 
Tertiary referral pathways have  
also been shown to be valuable.  
The campaign will promote tertiary 
referral centres to assist with 
interpretation of difficult imaging 
cases and explore ways to create 
greater access to diagnostic imaging 
interpretation support across the UK. 
graphic on diagnosis issues
of onset
Average age
A Gold Standard Approach
21
Our supporters
This document has been endorsed by key stakeholders in the field of musculoskeletal health, supporting the 
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Years for diagnosis of  
axial SpA is too long
Go to www.actonaxialspa.com for information and advice 
from some of the world’s leading experts on the condition.
Glossary of terms
All Party Parliamentary Group (APPG)  
All-Party Parliamentary Groups (APPGs) 
are informal cross-party groups that meet, 
relatively informally, to discuss a particular 
issue of concern. 
Acute anterior uveitis (AAU) 
Acute anterior uveitis is an eye condition 
caused by inflammation in the front part 
of the eye between the cornea (the clear 
window at the front of the eye) and the lens. 
It is also sometimes referred to as iritis.
Ankylosing spondylitis (AS) 
See axial spondyloarthritis
Axial spondyloarthritis (Axial SpA) 
Axial spondyloarthritis (axial SpA) is an 
inflammatory arthritis where the main 
symptom is back pain. Axial SpA is an 
umbrella term and it includes: ankylosing 
spondylitis (AS), where changes to the 
sacroiliac joints or the spine can be seen 
on x-ray and non-radiographic axial 
spondyloarthritis where x-ray changes are 
not present but inflammation is visible on MRI 
or you have symptoms.
Best MSK Health Collaborative  
This new initiative is part of the Pathways for 
Better Health Programme by NHS England, 
will significantly increase the resource to 
support MSK service delivery.
Biomarkers  
A biological molecule found in blood, other 
body fluids, or tissues that is a sign of a 
normal or abnormal process, or of a condition 
or disease.
Clinical Commissioning Groups (CCGs) 
NHS commissioning is the process of 
assessing needs, planning and prioritising, 
purchasing and monitoring health services. 
CCGs operate in England. 
Chiropractor 
Chiropractors are healthcare professionals 
who work to help treat problems with the 
bones, joints and muscles that support the 
body (the ‘musculoskeletal system’).
Classification criteria  
Classification criteria are standardised 
definitions that are primarily intended to 
create well-defined picture of the key shared 
features in the majority of patients with a 
disease or condition. 
CRP 
A CRP or c-reactive protein blood test is used 
to measure levels of inflammation.
Dactylitis 
Dactylitis is severe inflammation of the finger 
and/or toe joints.
Early arthritis initiative 
The National Early Inflammatory Arthritis Audit 
(NEIAA) aims to improve the quality of care 
for people living with inflammatory arthritis, 
collecting information on all new patients 
over the age of 16 in specialist rheumatology 
departments in England and Wales. It was 
commissioned by the Healthcare Quality 
Improvement Partnership as part of the 
National Clinical Audit Programme.
Enthesitis 
Enthesitis is inflammation of the entheses, 
the sites where tendons or ligaments insert 





Disease-related characteristics that are not 
related to the musculoskeletal system - in 
axial SpA this includes inflammatory bowel 
disease (IBD), psoriasis, and acute anterior 
uveitis (AAU). 
First Contact Practitioners 
First contact practitioners (FCPs) are 
experts in musculoskeletal health such 
as physiotherapists and osteopaths, who 
form part of a primary care practice. FCPs 
are usually the first health professional a 
patient will see in a GP practice about a 
musculoskeletal complaint. 
Generic back pain 
About 8 in 10 people have one or more bouts 
of low back pain over their lifetime. In most 
cases, it is not due to a serious disease or 
serious back problem, and the exact cause of 
the pain is not clear. This is called nonspecific 
or generic lower back pain. 
Getting It Right First Time (GIRFT)  
Getting It Right First Time (GIRFT) is a national 
programme designed to improve medical care 
within the NHS by reducing unwarranted 
variations. 
HCPs 
Health Care Professionals: anyone who is 
professionally qualified to deliver clinical / 
medical healthcare.
Health Education England’s Primary and 
Community Care Training Hubs 
Health Educations England’s training 
hubs provide the infrastructure for multi-
professional training and education in primary 
care to support recruitment, retention and 
return of all staff groups. 
HLA-B27/Human leukocyte antigen B27  
HLA-B27 gene 
There is a strong association between axial 
SpA and the HLA B27 gene. Although HLA B27 
is present in over 75% of people with axial 
SpA, only about 1 in 15 people who are HLA 
B27 positive go on to develop the condition. 
Inflammatory bowel disease / IBD 
Inflammatory bowel disease (IBD) is a term 
mainly used to describe two long-term 
conditions that involve inflammation of the 
gut: ulcerative colitis and Crohn’s disease.
Mechanical back pain 
Mechanical back pain arises from structural 
changes which may be in the spinal joints, 
vertebrae or soft tissues.
Musculoskeletal (MSK) 
Musculoskeletal (MSK) conditions affect the 
joints, bones and muscles.
Multiple sclerosis 
Multiple sclerosis (MS) is a condition that can 
affect the brain and spinal cord, causing a 
wide range of potential symptoms, including 
problems with vision, arm or leg movement, 
sensation or balance.
MRI / magnetic resonance imaging 
Magnetic resonance imaging (MRI) is a type 
of scan that uses strong magnetic fields and 
radio waves to produce detailed images of 
the inside of the body.
Osteopath /osteopathy 
Osteopaths are allied healthcare 
professionals, who are trained in the 
musculoskeletal (MSK) system and its 
relationship with other systems of the body.
Parkinson’s disease 
Parkinson’s disease is a brain disorder 
in which parts of the brain become 
progressively damaged over many years.
Peripheral arthritis  
Peripheral arthritis usually affects the large 
joints of the arms and legs, including the 
elbows, wrists, knees, and ankles. 
Peripheral musculoskeletal manifestations 
In axial SpA, peripheral manifestations  
include peripheral joint disease, enthesitis and 
dactylitis 
Psoriasis   
Psoriasis is an inflammatory skin condition 
that causes red, flaky, crusty patches of skin 
covered with silvery scales. 
Psoriatic arthritis (PsA) 
Psoriatic arthritis (PsA) affects joints (such 
as the knees or those in the hands and feet), 
as well as areas where tendons join to bone 
(such as the heel and lower back). 
Psychosomatic disorders 
A psychosomatic disorder is a physical illness 
which is caused or made worse by mental 
health. 
Radiography 
Radiography is an imaging technique using 
x-ray. 
Radiographic damage 
Where changes to the sacroiliac joints and 
spine can be seen on x-ray.
Rheumatologist / rheumatology 
Specialists in the diagnosis and treatment of 
conditions which affect the joints, muscles, 
and bones.
Sacroiliac joints / SIJs 
The sacroiliac joints at the base of the spine, 
connecting the spine to the hips.
SpA Academies 
SpA academy is a series of educational 
events relating to spondyloarthritis for health 
care professionals.
SPADE tool  
The SPADE tool is an online tool designed 
to assist medical professionals define the 
probability of axial spondyloarthritis.
Uveitis  
See acute anterior uveitis.
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